2020 Pharmaceutical Drug Patent Database - Active US & International Patents - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Drug Patent Database Subscription: Pharmaceutical Drugs" database has been added to ResearchAndMarkets.com's offering.

This subscription was created to answer a simple question: When do drug patents expire? Your needs evolve as the industry keeps changing. Since then dozens of additional datasets have been added by aggressive adaptation based on your needs.

This subscription for the Pharmaceutical Drugs portion of the database offers information on:

• US & International Patents, including active and expired patents in 134 Countries, regulatory protections and exclusivities;
• Information that anticipates drug entries into the generic market, including Loss-of-Exclusivity Dates, Paragraph IV Challenges, Tentative Approvals, Authorized Generics, and more.
• Commercial Opportunities, including Single Source Off-Patent Drugs, and the ability to search Patents by Dosage Form/Therapeutic Class
• Information on Drug Sourcing, including API Vendors, Finished Product Suppliers and First Generic Entrants.

Global biopharmaceutical markets face constant change. To remain competitive you need to anticipate what's next. The analyst understands and works together with you to help you make better decisions. If you are expanding into new markets, looking inward for growth opportunities, or seeking to improve your current activities and need to find information quickly, this subscription can help.

The analyst provides relevant context and ensures you have the information you need at your fingertips. This helps you see opportunities and enrich your analysis, without overwhelming you with options or asking you to perform many searches. The sophisticated algorithms are also tailored to help you extract valuable insights.

With a single click, you can find answers to complex questions such as:

• Which drugs have no patents and no competitors?
• What are all the patents covering any given dosage form (e.g. injectables)?
• What is the earliest generic entry opportunity date for a drug with dozens of patents?
• The analyst focuses on delivering the greatest value and lowest cost by directing attention to high-impact problems, giving you the relevant information you need.

The Pharmaceutical Drugs Plan Database helps drug companies make better decisions through the delivery of cutting-edge business intelligence. The Pharmaceutical Drug plan is focused on the interests of small-molecule drug manufacturers, suppliers, distributors, and payers.

The researcher is a provider of global business intelligence on biologic and small-molecule drugs, dedicated to helping clients make better decisions. Critical information on global drug patents is incorporated with litigation intelligence, drug prices, and historic sales figures to help users discover commercial opportunities and forecast future revenue events. Since 2005 the researcher has served hundreds of large and small companies in more than 65 countries.

Key Topics Covered:

• Expired, Pending, and Abandoned Patents
• Active US & International Patents
• Single Source Drugs, Tentative Approvals, Authorized Generics, Paragraph IV Challenges, and more.
• Clinical Trials
• API Vendors

Companies Mentioned

• 3M Pharmaceuticals
• Abbott Laboratories
• AbbVie
• Acadia Pharmaceuticals
• Acorda Therapeutics
• Actavis
• Actelion
• Adcock Ingram
• Advanced Chemical Industries
• Advaxis
• ACG Worldwide
• Ajanta Pharma
• Alcon
• Alembic Pharmaceuticals Ltd
• Alexion Pharmaceuticals
• Alkaloid AD Skopje
• Alkermes
• Allergan
• Alliance Boots
• Almirall
• Alphapharm
• Altana Pharma AG
• Amgen
• Anfatis
• Apotex Inc.
• Aspen Pharmacare
• Astellas Pharma
• AstraZeneca
• Aurobindo Pharma
• Avax Technologies
• Avella Specialty Pharmacy
• Axcan Pharma
• Bargn Farmaceutici Phils Co
• Barr Pharmaceuticals
• Bausch & Lomb
• Baxalta
• Baxter International
• Bayer Schering Pharma AG
• Beximco Pharmaceuticals Ltd
• Bial
• And Many More Companies!

For more information about this database visit https://www.researchandmarkets.com/r/nq0lm1